Ionis Pharmaceuticals, Inc.
NASDAQIonis Pharmaceuticals enters the back half of August with a genuine tension at its core: the stock is up 7.6% on the week and nearly 10% over the past month, yet short interest has climbed 28% over the same period and a fresh analyst initiation landed right at the current price. The most interesting signal on the positioning side is the divergence between short interest and borrow…
IONS short interest climbs 22% in one week to 12.1% of float, highest in 11 months, as stock falls 35% from recent highs amid Wainua setback and analyst downgrades.
Ionis Pharmaceuticals enters the back half of August with a genuine tension at its core: the stock is up 7.6% on the week and nearly 10% over the past month, yet short interest has climbed 28% over the same period and…
Ionis Pharmaceuticals heads into this week's earnings report with short interest at an 11-month high and the analyst community in near-uniform target-cutting mode — a combination that frames today's results as a…
Snapshot as of 23 Sept 2026
Ionis Pharmaceuticals heads into its July 29 earnings window with a notable shift in tone: short sellers have been covering and options traders have turned more bullish than they've been in months, yet the stock at…
Ionis Pharmaceuticals enters the back half of June with an interesting split: analyst conviction is rising, targets are moving higher, yet short sellers have been adding quietly and the stock has slipped 2% on the week…
Ionis Pharmaceuticals heads into the week after Q1 earnings with a notable divergence: the Street is growing more bullish while shorts are methodically unwinding, leaving the stock's $74.83 close roughly 25% below…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IONS — free to start on ORTEX.
Sign up for free →Open IONS on ORTEX